Oral magnesium supplementation in type II diabetic patients
Solati M, Ouspid E, Hosseini S, Soltani N, Keshavarz M, Dehghani M
Medical journal of the Islamic Republic of Iran · 34 citations
How it was studied
- Design
- Randomized controlled trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
Based on full-text disclosure statement.
Publication
- Published
- 2014-01-01 · Med J Islam Repub Iran · vol. 28 · issue 1 · p. 67
- Publisher
- National Institutes of Health
- Cited
- 71 citations · more than 90% of similar papers · 2.9× the field average
- References
- 25 works
- Access
- Open access (repository copy) · CC-BY-NC
- Research areas
- Magnesium in Health and Disease · Parathyroid Disorders and Treatments · Potassium and Related Disorders
- Keywords
- Medicine, Lipid profile, Internal medicine, Type 2 diabetes, Diabetes mellitus, Magnesium, Blood pressure, Hemoglobin, Endocrinology, Magnesium deficiency (plants), Placebo, Gastroenterology, Chemistry, Pathology
6 authors
From IR
- Mehrdad SolatiHormozgan University of Medical Sciences
- Elham OuspidHormozgan University of Medical Sciences
- Saeedeh Sadat HosseiniHormozgan University of Medical Sciences
- Nepton SoltaniHormozgan University of Medical Sciences
- Mansoor KeshavarzTehran University of Medical Sciences
- Mohsen DehghaniHormozgan University of Medical Sciences
Abstract
Background
Magnesium is the second most abundant intracellular cation. It plays an important role in insulin homeostasis and glucose metabolism through multiple enzymatic reactions. With increasing data on magnesium deficiency in diabetic patients and epidemiological studies demonstrating magnesium deficiency as a risk factor for diabetes, it is logical to search for its possible beneficial effects on diabetes control and prevention. We aimed to determine whether oral magnesium supplementation improves metabolic control, lipid profile and blood pressure in patients with type II diabetes.
Methods
Fifty four patients with type II diabetes were included in a randomized double blind placebocontrolled clinical trial.Patients received either placebo or 300 mg elemental magnesium (as magnesium sulfate -MgSo4-) daily, for 3 months. Metabolic control, lipid profile, blood pressure, magnesium status, hepatic enzymes, hemoglobin concentration, and anthropometric indices were determined in the beginning and at the end of the study.
Results
Daily administration of 300 mg elemental magnesium for 3 months, significantly improved fasting blood glucose (183.9±15.43 to 125.8±6.52 vs. 196.5±28.12 to 136.5±7.94, p< 0.0001), 2-hour post prandial glucose (239.1±74.75 to 189.1±60mg/dl vs. 246.4±97.37 to 247.8±86.74mg/dl, p< 0.01), lipid profile, blood pressure and hepatic enzymes.
Conclusion
Oral magnesium supplementation with proper dosage has beneficial effects on blood glucose, lipid profile, and blood pressure in patients with type II diabetes.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.